Work

Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.9089

Authors: Alberto Chiappori, Charles C. Williams, Ben C. Creelan, Tawee Tanvetyanon, Jhanelle Elaine Gray, Eric B. Haura, Ram Thapa, Dung-Tsa Chen, Amer A. Beg, Theresa A. Boyle, Jennifer Bendiske, Erick Morris, Aiyang Tao, Felipe K. Hurtado, Luigi Manenti, Julio Castro, Scott Joseph Antonia

Institutions: Moffitt Cancer Center, Novartis Institutes for BioMedical Research, Palobiofarma (Spain)

Language: English

Topic: Adenosine and Purinergic Signaling

Subfield: Physiology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890795012

Cites:

Cited by: 47

Related to: 10